Transforming growth factor-beta (TGF-b) signaling is dependent on the heterodimerization of the type II TGFb receptor (TbRII) with the type I TGF-b receptor (TbRI). Activated TbRI then mediates TGF-b signals by inducing the phosphorylation of Smad2 and/or Smad3, which separately hetetorodimerize with Smad4 and translocate to the nucleus. Phosphorylation of Smad2/ Smad3 by activated TbRI is inhibited by two newly discovered members of the Smad family, Smad6 and Smad7. We now report that Smad7 mRNA levels are increased in human pancreatic cancer by comparison with the normal pancreas, and that by in situ hybridization, Smad7 is over-expressed in the cancer cells within the tumor mass. Stable transfection of COLO-357 human pancreatic cancer cells with a fulllength Smad7 construct leads to complete loss of the growth inhibitory response to TGF-b1, without altering TGF-b1-mediated induction of PAI-I. Furthermore, Smad7 transfected COLO-357 cells display enhanced anchorage-independent growth and accelerated growth in nude mice. These ®ndings point to a previously unrecognized mechanism for selective suppression of TGF-b-mediated growth inhibition in cancer cells that allows for continued activation of the PAI-I promoter by TGF-b1, which may act to enhance the tumorigenicity of certain cancer cells.
Introduction
Transforming growth factor betas (TGF-bs) are multifunctional polypeptides that inhibit the growth of epithelial cells and exert multiple eects on the extracellular matrix (Sporn and Roberts, 1992; . Mammalian cells express TGF-b1, TGF-b2 and TGF-b3 isoforms that are synthesized as precursors and undergo proteolytic cleavage into biologically active dimers (Sporn and Roberts, 1992; . Binding of TGF-b dimers to the type II TGF-b receptor (TbRII) allows for its heterodimerization with the type I TGF-b receptor (TbRI), thereby activating TbRI and initiating a signaling cascade that is mediated by members of the Smad family of proteins (Heldin et al., 1997) . Activated TbRI induces the phosphorylation of Smad2 and Smad3, which separately hetetorodimerize with Smad4 (Heldin et al., 1997) . Smad2/Smad4 and Smad3/Smad4 complexes then translocate to the nucleus where they regulate gene transcription (Heldin et al., 1997; . Two novel members of the Smad family, Smad6 and Smad7, were cloned from vascular endothelial cells (Topper et al., 1996 Hayashi et al., 1997; Imamura et al., 1997) . They associate with the activated TbRI, thereby blocking access and phosphorylation of Smad2 (Hayashi et al., 1997; Imamura et al., 1997) and possibly Smad3. This prevents their interaction with Smad4, and blocks their subsequent nuclear translocation (Hayashi et al., 1997; Imamura et al., 1997) .
Pancreatic cancer is the ®fth leading cause of cancer death in the United States, with a mortality rate that virtually equals its incidence rate (Warshaw and Fernandez-del Castillo, 1992) . While the exact reasons for the biological aggressiveness of this malignancy have not been elucidated, these cancers often overexpress TGF-bs and this overexpression contributes to disease progression (Friess et al., 1993b) . As many as 50% of these cancers also harbor Smad4 mutations that render the cancer cells resistant to TGF-b-mediated growth suppression Schutte et al., 1996; Grau et al., 1997) . In addition, these cancers often express low levels of TbRI, which may also contribute to the loss of responsiveness to TGF-b1 (Baldwin et al., 1996; Wagner et al., 1998) . Recently, we reported that Smad6 expression is increased in pancreatic cancer (Klee et al., 1999) . We now report that Smad7 is also overexpressed in human pancreatic cancer, and that enhanced expression of Smad7 leads to loss of the TGF-b1-induced growth inhibition in COLO-357 pancreatic cancer cells without attenuating the actions of TGF-b1 on induction of PAI-I. We also show that Smad7 overexpressing clones exhibit increased anchorage-independent growth and accelerated growth in nude mice.
and a signal of moderate intensity in one normal sample ( Figure 1a ). In contrast, relatively high levels of this mRNA moiety were present in eight of 16 pancreatic cancer samples, while the remaining cancer samples exhibited moderate to low levels of the Smad7 mRNA transcript. There was a 3.6-fold increase (P50.01) in Smad7 mRNA levels in the eight cancer samples that exhibited a strong Smad7 signal by comparison with the corresponding levels in the normal controls. When data from all 16 cancer samples were analysed there was a 2.6-fold increase (P50.05) in Smad7 mRNA levels by comparison with the levels in the normal controls. To determine whether pancreatic cancer cells express Smad7 mRNA, Northern blot analysis of total RNA isolated from six pancreatic cancer cell lines was carried out. This analysis revealed that the Smad7 transcript was either present at very low levels in the cancer cells or below the level of detection (data not shown). In contrast, when Northern blotting was performed using poly(A) + RNA, the Smad7 transcript was evident in all the cell lines (Figure 1b) . ASPC-1, CAPAN-1, COLO-357, and PANC-1 cells expressed low levels of the Smad7 transcript, whereas MIA-PaCa-2 and T3M4 cells expressed even lower levels of this mRNA moiety (Figure 1b) .
In order to assess the exact sites of expression of Smad7 in cancer tissues, in situ hybridization was carried out in nine randomly selected cancer samples. In all nine samples, Smad7 mRNA was abundant in the cancer cells within the tumor mass (Figures 2a,c  and 3a ). Smad7 mRNA was also present to a lesser extent in the endothelial cells lining the associated blood vessels (Figure 2a, arrowheads) , in acinar and ductal cells adjacent to the cancer cells (Figure 3c ), and in some stromal ®broblasts (Figures 2a,c and 3a) . In contrast, Smad7 in situ hybridization signals were very faint in the normal pancreatic parenchyma, and were only consistently observed in the pancreatic islets (Figure 4) . In situ hybridization with sense probes were carried out with the corresponding serial sections, and did not reveal any speci®c signal (Figures 2b, d, 3b, d and 4b) .
Eects of over-expressing Smad7 in COLO-357 pancreatic cancer cells
To assess the potential role of high levels of Smad7 in pancreatic cancer cells in vivo, we next investigated the functional eects of Smad7 overexpression in COLO-357 pancreatic cancer cells. This cell line was chosen because it is growth inhibited by TGF-b and expresses a normal Smad4 gene (Baldwin et al., 1996; Baldwin and Korc, 1993; . Accordingly, COLO-357 cells were stably transfected with a fulllength Smad7 construct. Twenty independent COLO-357 clones were selected after 4 weeks of growth in selection medium. Subsequent experiments were carried out in four clones. These clones were selected because they displayed increased Smad7 mRNA levels by Northern blot analysis of total RNA (Figure 1c ) that were generally comparable to the levels observed in pancreatic cancers that over-expressed Smad7 by Northern blot analysis (Figure 1a) . TGF-b1 inhibited the growth of wild-type and sham transfected COLO-357 cells after a 72 h incubation, maximal eects occurring at a concentration of 1 nM TGF-b1 (741%; P50.01). In contrast, under the same conditions, TGF-b1 did not inhibit the growth of Smad7 over-expressing COLO-357 clones (Figure 5a ). TGF-b1 exerts its growth inhibitory eects in part by inducing the expression of proteins that suppress cell cycle progression, such as the cyclin dependent kinase (Cdk) inhibitor p21
Cip1 (Datto et al., 1995; Polyak et al., 1994) . Therefore, we next transiently transfected COLO-357 cells with the WWP-Lux luciferase reporter gene construct that contains the complete p21 promoter region (Reynisdottir et al., 1995) . Luciferase activity in this assay represents a measure of the responsiveness of the cells to TGF-b1 with respect to p21 Cip1 induction. Following 24 h of incubation with TGF-b1, there was a dose dependent increase in luciferase activity in COLO-357 and sham transfected cells, maximal eects occurring at 1 nM TGF-b1 (2.2-and 2.9-fold increase, respectively). In contrast, COLO-357 clones overexpressing Smad7 did Figure 1 Northern blot analysis. (a) Total RNA (20 mg/lane) from 12 normal pancreatic tissues, and 16 pancreatic cancers was subjected to Northern blot analysis using a 32 P-labeled Smad7 cDNA probe (500 000 c.p.m./ml). A 7S ribosomal cDNA probe (50 000 c.p.m./ml) was used as a loading and transfer control. Exposure times were 2 days for Smad7 and 6 h for 7S. (b) poly(A) + RNA (2 mg/lane) isolated from ASPC-1 (1), CAPAN-1 (2), COLO-357 (3), MIA-PaCa-2 (4), PANC-1 (5), and T3M4 (6) pancreatic cancer cell lines were analysed by Northern blotting using a 32 P-labeled Smad7 cDNA probe (500 000 c.p.m./ml). A human b-actin cDNA probe (50 000 c.p.m./ml) was used as a loading and transfer control. Exposure times were 1 day for Smad7 and 2 h for b-actin. (c) Total RNA (20 mg/lane) from parental (P), sham-transfected (S), and 4 Smad7 transfected clones as indicated of COLO-357 pancreatic cancer cells was subjected to Northern blot analysis using a 32 P-labeled Smad7 cDNA probe (500 000 c.p.m./ml). Exposure time was 2 days. Equal loading of lanes was con®rmed by ethidium bromide staining of the RNA not exhibit a signi®cant increase in luciferase activity following TGF-b1 addition ( Figure 5b ). In addition to modulating the expression of genes that regulate cell cycle progression, TGF-b1 induces the expression of a number of genes that contribute to the remodeling of the extracellular matrix . For example, TGF-b1 is known to induce the expression of PAI-I, which inhibits both tissue-type and urokinase-type plasminogen activators . Therefore, Northern blot analysis was carried out next in order to assess the eects of Smad7 on basal and TGF-b1-induced PAI-1 levels. Basal PAI-1 mRNA levels were higher in Smad7 transfected COLO-357 clones than in parental and sham transfected COLO-357 cells. Furthermore, TGF-b1 (100 pM) induced PAI-I mRNA expression in parental and sham transfected COLO-357 cells as well as in Smad7 transfected clones in a time-dependent manner ( Figure 6a ).
3TP-Lux is a luciferase reporter gene construct that contains three 12-O-tetradecanoylphorbol-13-acetate responsive elements from the human collagenase gene and one TGF-b responsive element from the human PAI-I gene (Wrana et al., 1992; Carcamo et al., 1994) . It is often used as a promoter element to test the transcriptional activity of TGF-b signaling, especially with respect to the eects of TGF-b on genes that regulate extracellular matrix formation (Wrana et al., 1992; Carcamo et al., 1994) . When wild-type and sham transfected COLO-357 cells were transiently transfected with 3TP-Lux, TGF-b1 exerted a dose dependent increase in luciferase activity, maximal eects occurring at a concentration of 100 pM TGF-b1. Basal luciferase activity was increased in the Smad7 transfected COLO-357 clones (data not shown). However, the presence of Smad7 did not alter the ability of TGF-b1 to increase luciferase activity ( Figure  6b ).
Next, we investigated anchorage-dependent and -independent growth characteristics of Smad7 transfected COLO-357 cells by measuring doubling times and colony forming eciencies in soft agar, respectively. Wild-type and sham transfected COLO-357 cells displayed exponential doubling times of 29 to 31 h. COLO-357 clones overexpressing Smad7 exhibited similar doubling times (30 to 38 h; data not shown). In contrast, wild-type and sham transfected COLO-357 cells displayed colony forming eciencies of *1.0%, whereas Smad7 transfected clones displayed significantly (P50.001) higher colony forming eciencies of 12 ± 14% (Figure 7a ).
To determine whether the enhanced anchorageindependent growth of Smad7 expressing COLO-357 clones resulted in enhanced tumorigenicity in vivo, 2610 6 parental, sham-transfected, and Smad7 transfected COLO-357 cells were injected subcutaneously in athymic (nude) mice at each site and tumor growth was measured weekly. Smad7 expressing COLO-357 clones exhibited earlier and more rapid tumor growth in comparison to sham transfected cells (Figure 7b ).
Discussion
Cell growth is modulated by positive and negative signals, and loss of negative growth constraints may contribute to the oncogenic process. Such perturbations may occur as a consequence of the loss of tumor suppressor gene function, including the loss of responsiveness to growth suppressing molecules such as TGF-bs (Reiss, 1997; White, 1998) . Resistance to Figure 4 In situ hybridization in the normal pancreas. Weak Smad7 mRNA in situ hybridization signals were present in the endocrine islets, shown outlined by solid arrowheads (a). In situ hybridization of serial sections with a Smad7 sense probe did not reveal any speci®c signal (b). Immunostaining of serial sections with anti-insulin antibodies con®rmed that the weak Smad7 signal was in the islets (c). Scale bar: 25 mm Smad7 in pancreatic cancer J Kleeff et al TGF-bs can occur through a variety of mechanisms. First, mutations within adenine mononucleotide repeat sequences in the TbRII gene commonly occur in colon and gastric cancer with mismatch repair de®ciencies and microsatellite instability (Markowitz et al., 1995) . These alterations, which lead to the synthesis of truncated receptors and loss of TGF-b1 responsiveness, are uncommon in pancreatic cancer (Venkatasubbarao et al., 1998; Goggins et al., 1998) . Second, decreased expression of either TbRI or TbRII has been implicated as a mechanism for TGF-b resistance in human tumors. TbRI underexpression occurs in prostate, colon, and pancreatic cancer cell lines, and in chronic lymphocytic leukemia cells (Baldwin et al., 1996; DeCoteau et al., 1997; Kim et al., 1996; Wang et al., 1996) , whereas TbRII levels are low in gastric cancer cells and in TGF-bresistant T-cell lymphoma cells (Kadin et al., 1994; Park et al., 1994) . Third, inactivating mutations in components of the TGF-b signaling pathway, such as Smad2 or Smad4 lead to a TGF-b-resistant state Eppert et al., 1996; Riggins et al., 1996; . Smad4 mutations are frequent in pancreatic cancer, and are also found in gastric and colorectal carcinomas, but less frequently in prostatic and esophageal cancers ; , 1997; Maesawa et al., 1997; .
In the present study, we determined that Smad7 mRNA levels were elevated in 50% of human pancreatic cancers. By in situ hybridization this overexpression occurred mainly in the pancreatic cancer cells within the tumor mass, and to a lesser extent in the stromal elements and acinar and ductal cells adjacent to the cancer cells. All nine tested pancreatic cancer samples, which were selected randomly, exhibited increased Smad7 expression in the cancer cells. This observation suggests that the magnitude and frequency of Smad7 overexpression in pancreatic cancer cells in vivo are greater than indicated by Northern blot analysis. To our knowledge, this represents the ®rst demonstration that Smad7 is overexpressed in cancer cells in any human malignancy.
In the present study the cultured pancreatic cancer cell lines expressed very low levels of Smad7, that generally were only detectable by Northern blotting of poly(A) + RNA. These low levels of endogenous Smad7 may explain the lack of correlation between Smad7 mRNA levels in these cells and responsiveness to TGFb1 (Baldwin et al., 1996) . These observations suggest that resistance to TGF-b-mediated growth inhibition in these cells was not Smad7-dependent. Instead, it was most likely caused by Smad4 mutations (ASPC-1 and CAPAN-1 cells; Schutte et al., 1996) , decreased expression of TbRI (T3M4 cells; Wagner et al., 1998) , or absence of TbRII (MIA-PaCa-2 cells; Freeman et al., 1995) . In contrast, Smad7 mRNA levels were increased in the pancreatic cancer cells in vivo, as documented by in situ hybridization. This dissociation between expression levels in cultured pancreatic cancer cells and in cancer cells within the tumor mass is not unique. For example, pancreatic cancer cells in vivo express high levels of EGF and IGF-1, whereas cultured pancreatic cancer cell lines do not express either growth factor (Korc et al., 1992; Bergmann et al., 1995) . While the mechanisms whereby pancreatic cancer cells overexpress Smad7 in vivo are not known, it has been recently shown that TGF-bs can induce the expression of Smad7 (Afrakhte et al., 1998) . It is possible therefore, that the overexpression of TGF-bs in the pancreatic cancers (Friess et al., 1993b) leads to autocrine and paracrine induction of Smad7 expression. It is unlikely that this induction is cancer cell speci®c inasmuch as the endothelial cells, acinar and ductal cells, and ®broblasts also exhibited expression of Smad7 by in situ hybridization. Indeed, Smad7 was originally cloned from endothelial cells and the enhanced expression in this cell type is believed to promote endothelial cell proliferation (Topper et al., 1996 .
To assess the consequence of Smad7 overexpression in pancreatic cancer cells, COLO-357 cells were transfected in a stable manner with a full-length Smad7 expression vector. In vitro, overexpression of Smad7 resulted in complete loss of the growth inhibitory response to TGF-b1 and a marked attenuation of the ability of TGF-b1 to activate WWP-Lux, a reporter gene construct that is under the control of the p21 promoter. In contrast, TGF-b1 was still capable of activating 3TP-Lux and inducing PAI-I mRNA expression levels in the Smad7 overexpressing cells. In addition, all the Smad7 overexpressing clones exhibited a marked increase in the capacity to form colonies in soft agar and tumors in nude mice, underscoring the potential of Smad7 to enhance the transformed phenotype of COLO-357 cells. Taken together, these observations indicate that enhanced expression of Smad7 can abrogate the growth suppressive eects of TGF-b1 in pancreatic cancer cells and point to a dissociation between the actions of Smad7 on cell growth and its eects on extracellular matrix regulating genes.
Our ®ndings in COLO-357 cells are in contrast with ®ndings in mink lung epithelial cells (Mv1Lu) and HUVEC, in which over-expression of Smad7 completely inhibits TGF-b-mediated PAI-I induction Hayashi et al., 1997; Itoh et al., 1998) . However, our ®ndings are in agreement with several previous reports. In Mv1Lu cells expression of a truncated TbRII or a mutant TbRI that lacks the juxtamembrane region preceding the GS domain does not attenuate TGF-b1 mediated induction of PAI-I (Yamamoto et al., 1996; Saitoh et al., 1996) . None- Figure 6 Eects of Smad7 on PAI-I induction and 3TP-luciferase activity. (a) Indicated clones of COLO-357 cells were serum starved overnight and incubated with 100 pM TGF-b1 for the indicated times. Total RNA (20 mg) was subjected to Northern blot analysis. Blots were hybridized with a 32 P-labeled cDNA probe speci®c for PAI-I (500 000 c.p.m./ml). Exposure times were 12 h. Equal loading of lanes was con®rmed by ethidium bromide staining of the RNA. (b) Following transient transfection with the 3TP-Lux construct, cells were incubated for 12 h in the absence (column 1) or presence of 10 pM, 100 pM, and 1 nM TGF-b1 (columns 2 ± 4, respectively). Data are expressed as mean+s.e.mean of three independent experiments. *P50.05 theless, these cells are resistant to the antiproliferative eects of TGF-b1 (Yamamoto et al., 1996; Saitoh et al., 1996) . Furthermore, transient overexpression of a Smad3 protein in which the three C-terminal serines have been replaced by aspartic acid blocks the antiproliferative eects of TGF-b1 in Mv1Lu cells, while still allowing for activation of PAI-I transcription (Liu et al., 1997) . Together, these observations suggest that PAI-1 induction and inhibition of proliferation by TGF-b represent distinct processes in certain cell types, including pancreatic cancer cells, and serve to underscore the multifunctional capabilities of TGF-b1 in dierent cell types.
PAI-I is the main inhibitor of the urokinase-type plasminogen activator system. It promotes cancer cell migration, invasion, and metastasis by blocking cellular adhesion and promoting basement membrane degradation in a variety of malignancies (Grondahl Hansen et al., 1997; Hofmann et al., 1996; Waltz et al., 1997).
TGF-b1 was able to activate the PAI-I promoter in Smad7 over-expressing cells, as illustrated in COLO-357 cells by an increase in PAI-1 mRNA levels and by increased 3TP-luciferase activity following TGF-b1 addition. These observations raise the possibility that Smad7 may confer a dual bene®t to pancreatic cancer cells. First, Smad7 acts to suppress TGF-b-mediated growth inhibition, by interfering with phosphorylation of Smad2/3 and subsequently blocking the ability of TGF-b to induce genes that inhibit cell cycle progression. Second, Smad7 does not prevent the ability of TGF-b1 to induce genes such as PAI-1, which may have the potential to promote cancer spread.
It has become increasingly evident that pancreatic cancers exhibit multiple alteration in the TGF-bsignaling pathway. Pancreatic cancers often overexpress TbRII (Friess et al., 1993a; Villanueva et al., 1998) , under-express TbRI (Baldwin et al., 1996; 2610 6 ) were injected at two sites subcutaneously in athymic nude mice and tumor growth was measured weekly until week 6. Tumor volume was determined by the equation: where l is length, h is height, and w is width of the tumor. Values are means+s.e.mean of six tumors/clone Smad7 in pancreatic cancer J Kleeff et al Wagner et al., 1998) , and overexpress all 3 TGF-b isoforms and Smad6 (Friess et al., 1993b; Klee et al., 1999) . These cancers also exhibit inactivating mutations of the Smad4 and p15 gene Villanueva et al., 1998) . In addition, pancreatic cancers express high levels of cyclin D1 (Gansauge et al., 1997; , which may also interfere with TGF-b signaling pathways (Okamoto et al., 1994) . In the present study we show that pancreatic cancers also commonly overexpress the TGF-b inhibitor Smad7. The reasons for the existence of redundant barriers to TGF-b signaling in pancreatic cancer are not readily evident. However, our observations point to complex regulatory mechanisms in the TGF-b signaling pathway in pancreatic cancer. Our ®ndings also suggest that Smad7 overexpression in pancreatic cancer cells in vivo may lead to enhanced tumor growth directly by rendering the cancer cells resistant to the growth inhibitory actions of TGF-bs, and indirectly by allowing for the expression of genes that promote tumor spread and metastasis.
Materials and methods

Materials
The following materials were purchased: FBS, RPMI and Dulbeccos Modi®ed Eagle (DME) medium, trypsin solution, penicillin ± streptomycin solution, and Geneticin (G418) from Irvine Scienti®c (Santa Ana, CA, USA); Genescreen membranes from New England Nuclear (Boston, MA, USA); restriction enzymes, random primed labeling kits, Genius 3 non-radioactive nucleic acid detection kits, and Genius 4 RNA labeling kits from Boehringer-Mannheim ( 
Tissue samples
Normal human pancreatic tissue samples (n=12; 7 male, 5 female donors; median age 41.8 years; range 16 ± 68 years) and human pancreatic cancer tissues (n=16; 10 male, 6 female; median age 62.6 years; range 53 ± 83 years) were obtained through an organ donor program and from pancreatic cancer patients undergoing surgery at the Department of Visceral and Transplantation Surgery, University of Bern. According to the TNM classi®cation of the Union Internationale Contre le Cancer (UICC) six tumors were stage 1, one stage 2, and nine stage 3 ductal adenocarcinomas. Freshly removed tissue samples were ®xed in 10% formaldehyde solution for 12 ± 24 h and paranembedded for histological analysis. In addition, tissue samples were frozen in liquid nitrogen immediately upon surgical removal and maintained at 780 8C until use for RNA extraction. All studies were approved by the Ethics Committee of the University of Bern and by the Human Subjects Committee at the University of California, Irvine.
RNA extraction and Northern blot analysis
Total RNA was extracted by the single step acid guadinium thiocyanate phenol chloroform method and poly(A) + RNA was prepared by anity chromatography on oligo-dT cellulose. Size fractioned RNA was electrotransferred onto nylon membranes. Blots were hybridized with a 32 P labeled Smad7 cDNA probe and exposed at 7808C to Kodak Biomax MS ®lms. A 190 bp 7S cDNA probe, and a 150 bp b-actin cDNA probe were used to con®rm equivalent loading of total RNA and poly(A) + RNA, respectively (Baldwin et al, 1996; Korc et al., 1992) .
In situ hybridization and immunostaining
Tissue sections (4 mm thick) were placed on 3-aminopropylmethoxysilane-coated slides, deparanized and incubated at 238C for 20 min with 0.2 N HCl and at 378C for 15 min with 40 mg/ml proteinase K. The sections were then post-®xed for 5 min in phosphate buered saline (PBS) containing 4% paraformaldehyde, and incubated brie¯y twice with PBS containing 2 mg/ml glycine and once in 50% (V/V) formamide/26SSC for 1 h. Hybridization was initiated by adding 100 ml hybridization buer containing the digoxigeninlabeled Smad7 riboprobe. The probes were labeled with digoxigenin-UTP by T7 or SP6 RNA polymerase using the Genius 4 RNA labeling kit. Hybridization was performed in a moist chamber for 16 h at 428C. The sections were then incubated for 60 min at 238C with 1% (w/v) blocking reagents, and for 30 min at 238C with a 1 : 2000 dilution of an alkaline phosphatase conjugated polyclonal sheep anti-digoxigenin Fab fragment antibody using the Genius 3 nonradioactive nucleic acid detection kit. Following a 2 ± 3 h incubation with color solution containing nitroblue tetrazolium and X-phosphate in a dark box, the sections were mounted in aqueous mounting medium . To localize the endocrine islets, immunostaining was carried out with anti-porcine insulin antibodies that are cross-reactive with human insulin, as previously reported .
Cell culture
Human pancreatic cancer cells were routinely grown in DMEM (COLO-357, MIA-PaCa-2, PANC-1) or RPMI (ASPC-1, CAPAN-1, T3M4) supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete medium). Growth assays were performed by incubating cells in serum-free medium (DMEM containing 0.1% BSA, 5 mg/ ml transferrin, 5 ng/ml sodium selenite, and antibiotics) in the absence or presence of TGF-b1, followed by addition of 3 -(4,5 -methylthiazol -2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, 62.5 mg/well) for 4 h. In pancreatic cancer cells the results of the MTT assay correlate with results obtained by cell counting with a hemocytometer and by monitoring [ 3 H]-thymidine incorporation (Raitano and Korc, 1990; Baldwin and Korc, 1993) . Basal anchorage-independent growth was assessed by a double soft agar assay . After 14 days colonies were counted by microscopy and stained with MTT solution for 12 h.
Growth in nude mice
Sham transfected or Smad7 transfected COLO-357 (2610 6 ) cells were injected subcutaneously into two sides of 4 ± 6 week old, female, athymic (nude) mice. The animals were monitored for tumor formation every week for 6 ± 8 weeks. Tumor volume was calculated as p/46width6height6length of the tumor .
Stable and transient transfections
Transfection of Smad7.pCI.neo into COLO-357 cells was carried out by the lipofectamine method. After reaching con¯uence, cells were split 1 : 10 in selection medium (complete medium supplemented with 0.5 mg/ml G418). Single clones were isolated after 2 ± 4 weeks. After clonal expansion, cells from each individual clone were screened for expression of Smad7 by Northern blot analysis. Parental COLO-357 cells were also transfected with a control expression vector containing the neomycin resistant gene (pRSVneo), and the resultant clones pooled and termed sham transfected. Positive clones were routinely grown in selection medium .
Transient transfections of COLO-357 cells were carried out with the p3TP-Lux or WWP-Lux plasmid. 3TP-Lux contains three 12-O-tetradecanoylphorbol-13-acetate responsive elements from the human collagenase gene and one TGF-b responsive element from the human plasminogen activator inhibitor-1 (PAI-1) promoter linked to the luciferase reporter gene (Wrana et al., 1992; Carcamo et al., 1994) . Increased luciferase activity following addition of TGF-b1 to cells transiently transfected with 3TP-Lux is generally taken to represent transcriptional TGF-b-responsiveness especially with respect to the regulation of extracellular matrix controlling genes such as PAI-1 and collagenase (Wrana et al., 1992; Carcamo et al., 1994) . WWP-Lux is a luciferase reporter gene under the control of the p21 promoter, which contains a p53 binding site (Reynisdottir et al., 1995) . Following transient transfection with WWP-Lux, increased luciferase activity in response to TGF-b1 is generally taken to represent transcriptional activation of p21 and p21-dependent pathways (Reynisdottir et al., 1995) . To carry out the assay, cells were plated overnight at a density of 25 000 cells/well in 24-well plates and transiently transfected with the p3TP-Lux or WWP-Lux plasmid using 1.5 ml/well lipofectamine and 0.5 mg plasmid/well in 500 ml serum free medium. Following a 5 h incubation, equal volumes of medium containing 20% FBS were added for 12 h. Cells were then incubated for 24 h in complete medium and subsequently incubated for 12 h in serum free medium prior to the addition of TGF-b1. Cells were solubilized in lysis buer containing 25 mM Tris HCl (pH 7.8), 2 mM DTT, 2 mM EGTA, 10% glycerol and 1% Triton X-100. Luciferase was assayed with a luminometer (Monolight 2010B: Analytical Luminescence Laboratory, San Diego, CA, USA) for 10 s after addition of the substrate solution containing 20 mM tricine, 1.07 mM magnesiumbicarbonate, 2.67 mM magnesium-sulfate, 0.1 mM EDTA, 530 mM ATP, 470 mM luciferin, 270 mM Coenzyme A (sodium salt), and 33.3 mM DTT as described (Wagner et al., 1998) .
Statistics
Student's t-test was used for statistical analysis, P50.05 was taken as the level of signi®cance. Results of MTT cell growth assays and luciferase reporter gene assays are expressed as mean+s.e.mean of at least three separate experiments.
